Alembic Pharmaceuticals received USFDA approval for its Sumatriptan injection, a generic equivalent for treating migraines and cluster headaches. This marks Alembic's first drug device combination.

Alembic Pharmaceuticals Limited has announced that it has received final approval from the US Food & Drug Administration ...

Ltd on Monday said it has received final approval from the US health regulator for its generic version of Sumatriptan injection used in treatment of migraine.   The approval by the US Food & Drug ...

Interior Health registered nurse Ilka Chobanova is a testament to how evidence-based best practices can improve patient ...

A team at St. Michael's Hospital in Toronto has successfully completed 10 brain angiograms using a robot controlled remotely ...

The latest announcement is out from Immutep Ltd ( (AU:IMM) ).

Once-daily, steroid-free topical foam intentionally formulated to help manage psoriasis across difficult-to-treat areas of ...

Indian stocks ended higher on Monday, with the Sensex and Nifty mirroring gains across Asian markets amid optimism that ...

As of September 30, 2025, Tonix had $190.1 million in cash and cash equivalents, compared with $98.8 million as of December 31, 2024. Net cash used in operations was approximately $60.2 million for ...

Detailed price information for Aim Immunotech Inc (AIM-A) from The Globe and Mail including charting and trades.

Vadodara: Pharma firm Alembic Pharmaceuticals Limited has announced that the company has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New ...

Cluster headache is one of the most severe and disabling primary headache disorders, though it often goes undiagnosed for years.